Sarepta will temporarily pause shipment of the gene therapy Elevidys in the United States.

Sarepta Therapeutics company announced on Monday that it will suspend all shipments of its Elevidys gene therapy in the United States following the death of a patient with muscular dystrophy who had received another experimental therapy. The US regulatory agency had requested for Sarepta Therapeutics to voluntarily stop its gene therapy last Friday, but the company initially refused. In a statement, Sarepta company said that all shipments of Elevidys drug used for treating Duchenne muscular dystrophy will temporarily stop by the end of the day on Tuesday.